The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity

The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eye (London) 2021-09, Vol.35 (9), p.2451-2453
Hauptverfasser: Ahmed, Shahanaz B., Higham, Aisling, Mulvihill, Alan, Chan, T. K. J., Adams, Gill, Patel, Chetan K.
Format: Artikel
Sprache:eng
Schlagworte:
692/699/3161/3175
692/700/1720
692/700/565/1436
Adults
Antibiotics
Cataracts
Comment
Consent
Drug dosages
Laboratory Medicine
Medical personnel
Medicine
Medicine & Public Health
Ophthalmology
Pediatrics
Pharmaceutical Sciences/Technology
Retinopathy
Surgery
Surgical Oncology
Surveillance
Vascular endothelial growth factor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2453
container_issue 9
container_start_page 2451
container_title Eye (London)
container_volume 35
creator Ahmed, Shahanaz B.
Higham, Aisling
Mulvihill, Alan
Chan, T. K. J.
Adams, Gill
Patel, Chetan K.
description
doi_str_mv 10.1038/s41433-021-01543-9
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562646693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-4446fbbf4e6c287f508e7e3e21a7cecaf738e948887e226c0ad570095bec8fad3</originalsourceid><addsrcrecordid>eNp9kc1OGzEUhS0EKin0BVigkdiwceu_sT0bJBQBrUBqF4C6sxznmgzKjAfbg5S3xyEUKAtW1tX57vE9OggdUPKdEq5_JEEF55gwigmtBcfNFppQoSSuRS220YQ0NcGMsb-76GtK94QUUZEvaJdzrRpd8wn6c72A6uayGqJ1uXVQBV-d9rnFt2cX51VeQLTDqvIhVjmCzR30eY1EyG0fBpsXq_U4ROhsHmObV_tox9tlgm8v7x66OT-7nv7EV78vfk1Pr7ATSmQshJB-NvMCpGNa-ZpoUMCBUascOOsV19AIrbUCxqQjdl4rUgLNwGlv53wPnWx8h3HWwdyVw6JdmiG2nY0rE2xr_lf6dmHuwqPRXClKWTE4fjGI4WGElE3XJgfLpe0hjMmwmkrGuOa8oEcf0Pswxr7EK5RkUkjZrCm2oVwMKUXwr8dQYtaFmU1hphRmngszTVk6fB_jdeVfQwXgGyAVqb-D-Pb3J7ZPQHOhwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562646693</pqid></control><display><type>article</type><title>The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity</title><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ahmed, Shahanaz B. ; Higham, Aisling ; Mulvihill, Alan ; Chan, T. K. J. ; Adams, Gill ; Patel, Chetan K.</creator><creatorcontrib>Ahmed, Shahanaz B. ; Higham, Aisling ; Mulvihill, Alan ; Chan, T. K. J. ; Adams, Gill ; Patel, Chetan K.</creatorcontrib><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-021-01543-9</identifier><identifier>PMID: 33879853</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/3161/3175 ; 692/700/1720 ; 692/700/565/1436 ; Adults ; Antibiotics ; Cataracts ; Comment ; Consent ; Drug dosages ; Laboratory Medicine ; Medical personnel ; Medicine ; Medicine &amp; Public Health ; Ophthalmology ; Pediatrics ; Pharmaceutical Sciences/Technology ; Retinopathy ; Surgery ; Surgical Oncology ; Surveillance ; Vascular endothelial growth factor</subject><ispartof>Eye (London), 2021-09, Vol.35 (9), p.2451-2453</ispartof><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021</rights><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-4446fbbf4e6c287f508e7e3e21a7cecaf738e948887e226c0ad570095bec8fad3</citedby><cites>FETCH-LOGICAL-c474t-4446fbbf4e6c287f508e7e3e21a7cecaf738e948887e226c0ad570095bec8fad3</cites><orcidid>0000-0002-7931-7208 ; 0000-0002-1409-6045 ; 0000-0003-1619-798X ; 0000-0002-8901-0007</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377112/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377112/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33879853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmed, Shahanaz B.</creatorcontrib><creatorcontrib>Higham, Aisling</creatorcontrib><creatorcontrib>Mulvihill, Alan</creatorcontrib><creatorcontrib>Chan, T. K. J.</creatorcontrib><creatorcontrib>Adams, Gill</creatorcontrib><creatorcontrib>Patel, Chetan K.</creatorcontrib><title>The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><subject>692/699/3161/3175</subject><subject>692/700/1720</subject><subject>692/700/565/1436</subject><subject>Adults</subject><subject>Antibiotics</subject><subject>Cataracts</subject><subject>Comment</subject><subject>Consent</subject><subject>Drug dosages</subject><subject>Laboratory Medicine</subject><subject>Medical personnel</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Ophthalmology</subject><subject>Pediatrics</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Retinopathy</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Surveillance</subject><subject>Vascular endothelial growth factor</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1OGzEUhS0EKin0BVigkdiwceu_sT0bJBQBrUBqF4C6sxznmgzKjAfbg5S3xyEUKAtW1tX57vE9OggdUPKdEq5_JEEF55gwigmtBcfNFppQoSSuRS220YQ0NcGMsb-76GtK94QUUZEvaJdzrRpd8wn6c72A6uayGqJ1uXVQBV-d9rnFt2cX51VeQLTDqvIhVjmCzR30eY1EyG0fBpsXq_U4ROhsHmObV_tox9tlgm8v7x66OT-7nv7EV78vfk1Pr7ATSmQshJB-NvMCpGNa-ZpoUMCBUascOOsV19AIrbUCxqQjdl4rUgLNwGlv53wPnWx8h3HWwdyVw6JdmiG2nY0rE2xr_lf6dmHuwqPRXClKWTE4fjGI4WGElE3XJgfLpe0hjMmwmkrGuOa8oEcf0Pswxr7EK5RkUkjZrCm2oVwMKUXwr8dQYtaFmU1hphRmngszTVk6fB_jdeVfQwXgGyAVqb-D-Pb3J7ZPQHOhwQ</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Ahmed, Shahanaz B.</creator><creator>Higham, Aisling</creator><creator>Mulvihill, Alan</creator><creator>Chan, T. K. J.</creator><creator>Adams, Gill</creator><creator>Patel, Chetan K.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7931-7208</orcidid><orcidid>https://orcid.org/0000-0002-1409-6045</orcidid><orcidid>https://orcid.org/0000-0003-1619-798X</orcidid><orcidid>https://orcid.org/0000-0002-8901-0007</orcidid></search><sort><creationdate>20210901</creationdate><title>The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity</title><author>Ahmed, Shahanaz B. ; Higham, Aisling ; Mulvihill, Alan ; Chan, T. K. J. ; Adams, Gill ; Patel, Chetan K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-4446fbbf4e6c287f508e7e3e21a7cecaf738e948887e226c0ad570095bec8fad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/699/3161/3175</topic><topic>692/700/1720</topic><topic>692/700/565/1436</topic><topic>Adults</topic><topic>Antibiotics</topic><topic>Cataracts</topic><topic>Comment</topic><topic>Consent</topic><topic>Drug dosages</topic><topic>Laboratory Medicine</topic><topic>Medical personnel</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Ophthalmology</topic><topic>Pediatrics</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Retinopathy</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Surveillance</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Shahanaz B.</creatorcontrib><creatorcontrib>Higham, Aisling</creatorcontrib><creatorcontrib>Mulvihill, Alan</creatorcontrib><creatorcontrib>Chan, T. K. J.</creatorcontrib><creatorcontrib>Adams, Gill</creatorcontrib><creatorcontrib>Patel, Chetan K.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Databases</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Shahanaz B.</au><au>Higham, Aisling</au><au>Mulvihill, Alan</au><au>Chan, T. K. J.</au><au>Adams, Gill</au><au>Patel, Chetan K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>35</volume><issue>9</issue><spage>2451</spage><epage>2453</epage><pages>2451-2453</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33879853</pmid><doi>10.1038/s41433-021-01543-9</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-7931-7208</orcidid><orcidid>https://orcid.org/0000-0002-1409-6045</orcidid><orcidid>https://orcid.org/0000-0003-1619-798X</orcidid><orcidid>https://orcid.org/0000-0002-8901-0007</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-222X
ispartof Eye (London), 2021-09, Vol.35 (9), p.2451-2453
issn 0950-222X
1476-5454
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377112
source PubMed Central; SpringerLink Journals - AutoHoldings
subjects 692/699/3161/3175
692/700/1720
692/700/565/1436
Adults
Antibiotics
Cataracts
Comment
Consent
Drug dosages
Laboratory Medicine
Medical personnel
Medicine
Medicine & Public Health
Ophthalmology
Pediatrics
Pharmaceutical Sciences/Technology
Retinopathy
Surgery
Surgical Oncology
Surveillance
Vascular endothelial growth factor
title The UK practice of Anti-VEGF therapy for treatment of retinopathy of prematurity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A01%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20UK%20practice%20of%20Anti-VEGF%20therapy%20for%20treatment%20of%20retinopathy%20of%20prematurity&rft.jtitle=Eye%20(London)&rft.au=Ahmed,%20Shahanaz%20B.&rft.date=2021-09-01&rft.volume=35&rft.issue=9&rft.spage=2451&rft.epage=2453&rft.pages=2451-2453&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-021-01543-9&rft_dat=%3Cproquest_pubme%3E2562646693%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2562646693&rft_id=info:pmid/33879853&rfr_iscdi=true